Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma

This study provides a data-driven prioritization of ADCs targets that will facilitate clinicians and drug developers in deciding which ADC should be taken for further clinical evaluation in HNSCC. This might help to improve disease outcome of HNSCC patients.